TY - JOUR
T1 - Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology
T2 - European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated January 2017
AU - Dumonceau, Jean-Marc
AU - Deprez, Pierre H
AU - Jenssen, Christian
AU - Iglesias-Garcia, Julio
AU - Larghi, Alberto
AU - Vanbiervliet, Geoffroy
AU - Aithal, Guruprasad P
AU - Arcidiacono, Paolo G
AU - Bastos, Pedro
AU - Carrara, Silvia
AU - Czakó, László
AU - Fernández-Esparrach, Gloria
AU - Fockens, Paul
AU - Ginès, Àngels
AU - Havre, Roald F
AU - Hassan, Cesare
AU - Vilmann, Peter
AU - van Hooft, Jeanin E
AU - Polkowski, Marcin
N1 - © Georg Thieme Verlag KG Stuttgart · New York.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - MAIN RECOMMENDATIONS For pancreatic solid lesions, ESGE recommends performing endoscopic ultrasound (EUS)-guided sampling as first-line procedure when a pathological diagnosis is required. Alternatively, percutaneous sampling may be considered in metastatic disease. Strong recommendation, moderate quality evidence. In the case of negative or inconclusive results and a high degree of suspicion of malignant disease, ESGE suggests re-evaluating the pathology slides, repeating EUS-guided sampling, or surgery. Weak recommendation, low quality evidence. In patients with chronic pancreatitis associated with a pancreatic mass, EUS-guided sampling results that do not confirm cancer should be interpreted with caution. Strong recommendation, low quality evidence. For pancreatic cystic lesions (PCLs), ESGE recommends EUS-guided sampling for biochemical analyses plus cytopathological examination if a precise diagnosis may change patient management, except for lesions≤10mm in diameter with no high risk stigmata. If the volume of PCL aspirate is small, it is recommended that carcinoembryonic antigen (CEA) level determination be done as the first analysis. Strong recommendation, low quality evidence. For esophageal cancer, ESGE suggests performing EUS-guided sampling for the assessment of regional lymph nodes (LNs) in T1 (and, depending on local treatment policy, T2) adenocarcinoma and of lesions suspicious for metastasis such as distant LNs, left liver lobe lesions, and suspected peritoneal carcinomatosis. Weak recommendation, low quality evidence. For lymphadenopathy of unknown origin, ESGE recommends performing EUS-guided (or alternatively endobronchial ultrasound [EBUS]-guided) sampling if the pathological result is likely to affect patient management and no superficial lymphadenopathy is easily accessible. Strong recommendation, moderate quality evidence. In the case of solid liver masses suspicious for metastasis, ESGE suggests performing EUS-guided sampling if the pathological result is likely to affect patient management, and (i) the lesion is poorly accessible/not detected at percutaneous imaging, or (ii) a sample obtained via the percutaneous route repeatedly yielded an inconclusive result. Weak recommendation, low quality evidence.
AB - MAIN RECOMMENDATIONS For pancreatic solid lesions, ESGE recommends performing endoscopic ultrasound (EUS)-guided sampling as first-line procedure when a pathological diagnosis is required. Alternatively, percutaneous sampling may be considered in metastatic disease. Strong recommendation, moderate quality evidence. In the case of negative or inconclusive results and a high degree of suspicion of malignant disease, ESGE suggests re-evaluating the pathology slides, repeating EUS-guided sampling, or surgery. Weak recommendation, low quality evidence. In patients with chronic pancreatitis associated with a pancreatic mass, EUS-guided sampling results that do not confirm cancer should be interpreted with caution. Strong recommendation, low quality evidence. For pancreatic cystic lesions (PCLs), ESGE recommends EUS-guided sampling for biochemical analyses plus cytopathological examination if a precise diagnosis may change patient management, except for lesions≤10mm in diameter with no high risk stigmata. If the volume of PCL aspirate is small, it is recommended that carcinoembryonic antigen (CEA) level determination be done as the first analysis. Strong recommendation, low quality evidence. For esophageal cancer, ESGE suggests performing EUS-guided sampling for the assessment of regional lymph nodes (LNs) in T1 (and, depending on local treatment policy, T2) adenocarcinoma and of lesions suspicious for metastasis such as distant LNs, left liver lobe lesions, and suspected peritoneal carcinomatosis. Weak recommendation, low quality evidence. For lymphadenopathy of unknown origin, ESGE recommends performing EUS-guided (or alternatively endobronchial ultrasound [EBUS]-guided) sampling if the pathological result is likely to affect patient management and no superficial lymphadenopathy is easily accessible. Strong recommendation, moderate quality evidence. In the case of solid liver masses suspicious for metastasis, ESGE suggests performing EUS-guided sampling if the pathological result is likely to affect patient management, and (i) the lesion is poorly accessible/not detected at percutaneous imaging, or (ii) a sample obtained via the percutaneous route repeatedly yielded an inconclusive result. Weak recommendation, low quality evidence.
KW - Abdomen
KW - Digestive System Neoplasms/diagnostic imaging
KW - Endosonography
KW - Gastroenterology/standards
KW - Humans
KW - Image-Guided Biopsy/standards
KW - Lymphadenopathy/diagnostic imaging
KW - Mediastinum
KW - Pancreatic Cyst/diagnostic imaging
U2 - 10.1055/s-0043-109021
DO - 10.1055/s-0043-109021
M3 - Journal article
C2 - 28511234
SN - 0013-726X
VL - 49
SP - 695
EP - 714
JO - Endoscopy
JF - Endoscopy
IS - 7
ER -
